Pyc Therapeutics Share Price and Company Fundamentals



Price
$0.125
Change
-0.010 (-7.407%)
52 week
0.125 - 0.19

Last traded: Today at 5:10 AM

PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and VP-002, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for retinal and central nervous system diseases. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Key Metrics

PE ratio

-

PB ratio

8.78

Dividend yield

Beta

0.31

Market cap

-

Enterprise value

-

Company profile

Primary activitiesBiotechnology research and development Peptide drug discovery
Industry / SectorBiotechnology / Healthcare
Websitehttps://pyctx.com
Mailing addressHarry Perkins Institute 6 Verdun Street Nedlands WA 6009 Australia
Phone / Fax61 8 6151 0992 / 61 8 9315 5475
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Pyc Therapeutics does not pay dividends.

Company Executives

As of Jan 2022, following are the company executives and directors listed on Pyc Therapeutics.

NameTitleAgeTotal Pay
Mr. Sahm Nasseri M.B.A., MBACEO of US operations37689.4k
Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.)CEO & Exec. Director38
Mr. Kevin Ronald Hart B.Com, B.Comm (Hons), C.A., F.C.A., FCACompany Sec. & CFO59
Prof. Sue FletcherChief Scientific Officer
Mr. Kaggen Ausma L.L.B.Chief Bus. Officer
Dr. May Orfali M.B.A., M.D.Chief Medical Officer of US Operations
Dr. Glenn NoronhaChief Devel. Officer56

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-610.16%

Return on assets

-26.20%

Return on equity

-44.29%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Pyc Therapeutics is and its enterprise value is .

The PYC's stocks Beta value is 0.31 making it 69% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Pyc Therapeutics (PYC)

Pyc Therapeutics (ASX:PYC) Frequently Asked Questions

1. What is Pyc Therapeutics's Stock Symbol?

Pyc Therapeutics trades on ASX under the ticker symbol "PYC".

2. What is Pyc Therapeutics's stock price today?

One share of PYC stock can currently be purchased for approximately $0.125.

3. How can I contact Pyc Therapeutics?

Pyc Therapeutics's mailing address is Harry Perkins Institute 6 Verdun Street Nedlands WA 6009 Australia. The company can be reached via phone at 61 8 6151 0992.

4. What is Pyc Therapeutics's official website?

The official website of Pyc Therapeutics is https://pyctx.com.

5. Which share registry manages Pyc Therapeutics's stock?

Pyc Therapeutics's stock is managed by AUTOMIC REGISTRY SERVICES.